Long-Term Safety and Efficacy of Percutaneous Left Atrial Appendage Closure with the LAmbre Device.

Guangji Wang,Bin Kong,Yu Liu,He Huang,Amit Segev

doi:10.1155/2020/6613683

Guangji Wang, Bin Kong + Show 3 more

Open Access

https://doi.org/10.1155/2020/6613683

Copy DOI

Abstract

Background Left atrial appendage closure (LAAC) using the LAmbre device has been associated with prevention of stroke in patients with nonvalvular atrial fibrillation (AF). Here, we interrogated the long-term safety and efficacy of using the LAmbre device in percutaneous LAAC. Methods We analyzed 56 records of patients with nonvalvular AF undergoing LAAC procedures with the LAmbre device. We collected and analyzed the data to define the safety and efficacy of the LAmbre device implantation. Result The LAAC was successfully occluded in the 56 patients. Our data showed no serious residual leak or pericardial effusion occurred during the perioperative period. At a mean follow-up of 37.8 ± 23.5 months, there were 7.1%, 3.6%, and 3.6% rates of death, stroke, and device-related thrombus, respectively. There were no cases of severe residual leak or systemic embolism. Conclusion Taken together, we demonstrate that execution of LAAC with the LAmbre device has high procedural success and prevents AF-related stroke. However, further large-scale trials might be required to confirm our findings.

Highlights

Atrial fibrillation (AF) is the most common sustained arrhythmia, which is associated with an increased risk of stroke [1]
For patients contraindicated with oral anticoagulation (OAC) or those who refuse OAC therapy, left atrial appendage closure (LAAC) with Watchman (Boston Scientific, Natick, Massachusetts) or Amplatzer Cardiac Plug
Previous studies have confirmed that Left atrial appendage closure (LAAC) with the LAmbre is safe and effective in the prevention of thromboembolic events [11,12,13], but the effectiveness and the safety were similar to Watchman and Amplatzer Cardiac Plug (ACP) [14]

Summary

Introduction

Atrial fibrillation (AF) is the most common sustained arrhythmia, which is associated with an increased risk of stroke [1]. Previous studies have confirmed that LAAC with the LAmbre is safe and effective in the prevention of thromboembolic events [11,12,13], but the effectiveness and the safety were similar to Watchman and ACP [14]. There are no data on the longterm safety and efficacy of LAAC with the LAmbre occluder in patients with AF. Left atrial appendage closure (LAAC) using the LAmbre device has been associated with prevention of stroke in patients with nonvalvular atrial fibrillation (AF). We interrogated the long-term safety and efficacy of using the LAmbre device in percutaneous LAAC. We collected and analyzed the data to define the safety and efficacy of the LAmbre device implantation. We demonstrate that execution of LAAC with the LAmbre device has high procedural success and prevents AF-related stroke. Further large-scale trials might be required to confirm our findings

Objectives

Methods

Results

Conclusion